NuVasive Does Not Expect Full Recovery in 2020

NuVasive logo

NuVasive reported 2Q20 orthopedic revenue of USD $203.6 million, -30.3% vs. 2Q19. The company saw monthly volume improvements throughout the quarter but took a more conservative view of recovery prospects for 2H20 compared to its peers. NuVasive’s volumes declined to -70% in April but worked back to low double-digit declines in June. The...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us